CARTALAX
Also known as
Short peptide studied for cartilage and connective tissue recovery. Preliminary evidence — investigational stage; evidence base is largely preclinical.
Evidence
Animal or in-vitro only
Risk band
Known AEs, monitoring advised
Research goals
Summary
Cartalax is a short synthetic Khavinson-type peptide (AED), and the available evidence is entirely preclinical, based on in-vitro cell cultures and animal tissue explants rather than human trials. In these models, AED and related short peptides such as KE, KED, and AEDG modulated cell renewal, proliferation, and aging markers, including effects on neuronal differentiation markers in stem cells [1], proliferation and apoptosis in kidney tissue cultures from young and old animals [2], and matrix and aging-related gene and protein expression in skin fibroblasts [3] and mesenchymal stem cells [4]. No randomized controlled trials, meta-analyses, or human interventional studies of administering Cartalax as a therapeutic are present, so any clinical benefit in humans remains unestablished and the evidence should be regarded as exploratory.
Sources
- 1. Effect of short peptides on neuronal differentiation of stem cells International journal of immunopathology and pharmacology, 2019.
- 2. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals Bulletin of experimental biology and medicine, 2015.
- 3. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro Bulletin of experimental biology and medicine, 2016.
- 4. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides Molecular biology reports, 2020.
For educational purposes only.